Augmenix wins FDA nod for SpaceOar prostate treatment
FDA clearance in hand, Augmenix is formulating U.S. commercial sales and insurance reimbursement plans for a medical gel designed to
Pioneering Medical Innovations
Pioneering Medical Innovations
FDA clearance in hand, Augmenix is formulating U.S. commercial sales and insurance reimbursement plans for a medical gel designed to
First-of-its-kind Treatment Offers Significant Clinical Benefits to Prostate Cancer Patients Undergoing Radiotherapy WALTHAM, Mass.—April 2, 2015—Augmenix, Inc., a privately held
— Topline results of the second Phase 3 clinical trial expected by the end of March — — NDA submission
WASHINGTON, D.C.— The American Institute for Medical and Biological Engineering (AIMBE) has announced the pending induction of Amar Sawhney, Ph.D., CEO,
CAMPBELL, Calif., Jan. 13, 2015 /PRNewswire/ — Apama Medical, Inc., a privately held medical device company focused on the development of
OTX-DP Demonstrated Statistically Significant Therapeutic Effect for Ocular Itching and Conjunctival Redness over Six Weeks with a Single Dose BEDFORD,
DUBLIN, Ohio, Sept. 25, 2014 /PRNewswire/ — AccessClosure, a Cardinal Health company, recently won the Emerging Growth Company Award from Phoenix,
Clinical Trial is First to Definitively Demonstrate That Removing Embolic Debris from Cerebral Circulation Can Significantly Shield the Brain TCT
With his roots at stent pioneer Advanced Cardiovascular Systems and medical device experience spanning almost 30 years, Silicon Valley entrepreneur
Ocular Therapeutix, which develops and markets eye therapeutics using its sustained-release hydrogel platform, filed on Friday with the SEC to